COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03639181
Recruitment Status : Recruiting
First Posted : August 21, 2018
Last Update Posted : December 18, 2019
Information provided by (Responsible Party):
Genor Biopharma Co., Ltd.

Tracking Information
First Submitted Date  ICMJE August 13, 2018
First Posted Date  ICMJE August 21, 2018
Last Update Posted Date December 18, 2019
Actual Study Start Date  ICMJE October 15, 2018
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 13, 2019)
Objective Response Rate, ORR [ Time Frame: up to 52 weeks ]
To evaluate the efficacy of GB226 as defined by objective response rate, in patients with B-NHL.
Original Primary Outcome Measures  ICMJE
 (submitted: August 16, 2018)
ORR [ Time Frame: up to 52 weeks ]
Objective response rate in accordance with RECIST 1.1
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 13, 2019)
  • Duration of response, DOR [ Time Frame: up to 52 weeks ]
    To evaluate the duration of response (DOR) of GB242 in patients with B-NHL.
  • Overall survival, OS [ Time Frame: up to 52 weeks ]
    To evaluate the duration from the first administration to death because of any reason in patients with B-NHL.
  • Progression-free survival, PFS [ Time Frame: up to 52 weeks ]
    To evaluate the efficacy of GB226 as defined by progression-free survival, in patients with B-NHL.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 16, 2018)
  • PFS [ Time Frame: up to 52 weeks ]
    Progression-free survival
  • DOR [ Time Frame: up to 52 weeks ]
    duration of response
  • DCR [ Time Frame: up to 52 weeks ]
    disease control rate
  • Assessment of safety parameters [ Time Frame: up to 52 weeks ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  • Immunogenicity of Gxplore-003 [ Time Frame: up to 52 weeks ]
    Percentage of patients who develop anti-GB226 antibodies (ADA)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Official Title  ICMJE A Study to Evaluate the Efficacy and Safety of Genormab Injection in Chinese Patients With Recurrent or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Brief Summary An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)
Detailed Description GB226, 3mg/kg/time, is intravenously infused once every two weeks until disease progression, intolerable toxicity or study withdrawal decided by the investigator/subject. It is expected that each subject will be followed for 2 years. Subjects receiving GB226 treatment will be followed once every 2 weeks to the end of this study. If the patients terminate the treatment and their imaging assessment shows no progressive disease (PD), they should be followed once every 6 weeks until progressive disease (imaging evaluation). If the patients have progressive disease (imaging assessment), they should be followed every 3 months until the end of this study or premature withdrawal from the study. Relevant tests and evaluation should be completed at each visit according to standard of care. The follow-up visits can be performed by telephone. During the study, subjects must complete one imaging test and efficacy evaluation every 6 weeks until disease progression. Moreover, patients should be closely monitored for adverse events from subject enrollment to 30 days after the last dosing
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE B-cell Non-Hodgkin's Lymphoma
Intervention  ICMJE Biological: GB226
3mg/kg treat every 2 weeks
Other Name: Geptanolimab Injection
Study Arms  ICMJE Experimental: GB226 3mg/kg every 2 weeks
Geptanolimab Injection, 3mg/kg every 2 weeks
Intervention: Biological: GB226
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 16, 2018)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 30, 2020
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥18 years old, male or female;
  2. Understanding of procedures and contents of the study, and voluntary signing of written informed consent form;
  3. Histopathologically confirmed Primary Mediastinal B-cell Lymphoma (PMBCL):
  4. Consent to provide archived tumor tissue samples or fresh tissue samples;
  5. ECOG score: 0-1;
  6. Expected survival ≥ 3 months;
  7. Computed tomography scans performed within 28 days prior to study enrollment should show at least one tumor lesion that can be clearly measured in two perpendicular directions. The longest diameter of intranodal lesion is >1.5 cm, and the longest diameter of extranodal lesion is >1.0 cm (according to the 2014 lugano standard);
  8. Blood routine requirements: hemoglobin ≥80 g/L, neutrophil ≥1.0 × 109 /L, platelet ≥75× 109 /L (before test)No blood transfusion or biostimulant for 14 days);
  9. Serum creatinine ≤1.5 ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula)
  10. Total bilirubin ≤1.5 ULN (Gilbert syndrome allows ≤5 ULN), aspartic acid transaminase (AST)ALT≤ 2.5 ULN (AST and/or ALT≤5×ULN is allowed in patients with liver metastasis)
  11. Thyroid function indexes: thyrotropic hormone (TSH) and free thyroxine (FT3/FT4) were in the normal range.If TSH and FT3 are not in the normal range, FT4 can be included.
  12. Women should be confirmed not pregnant within 7 days before administration; both males and females agree to do effective contraceptive measures during the trial and 6 months after completion;
  13. Patients were able to visit according to the schedule and communicate well with the investigator and complete the study in accordance with the protocol

Exclusion Criteria:

  1. Patients with history of other malignant tumors (except cured cervical cancer in situ, basal cell carcinoma or squamous epithelial cancer) may not participate in the study unless complete response lasts for at least 2 years prior to enrollment, and it is estimated that no other treatment will be required throughout the study;
  2. Definite central nervous system (CNS) infiltration of lymphoma, including brain parenchyma, meningeal invasion or spinal cord compression;
  3. Systemic chemotherapy and targeted therapy were carried out within 2 weeks before the experimental medication, and radical/generalized radiotherapy was carried out within 4 weeks.Anti-tumor biotherapy (tumor vaccine, cytokines or growth factors for the purpose of tumor control); In 1 weeksLocal palliative radiotherapy;
  4. A systemic corticosteroid (prednisone >10 mg/ d or equivalent) was administered within 2 weeks before administration;
  5. Autologous hematopoietic stem cell transplantation was performed within 2 months and allogeneic hematopoietic stem cell transplantation was performed within 5 years plant;
  6. Major surgery under general anesthesia was performed within 4 weeks before the trial. Local anesthesia/epidural anesthesia within 2 weeks surgery
  7. Active, known history of autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, and type iiRheumatoid arthritis, inflammatory bowel disease, hashimoto's thyroiditis, etc., except: type 1 diabetes, only through hormonesHypothyroidism that can be controlled with alternative therapies, skin diseases that do not require systemic treatment (e.g. vitiligo, psoriasis),Controlled celiac disease or disease in which no recurrence is expected without an external stimulus
  8. Uncontrolled hypertension (systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg) or pulmonary hypertension orUnstable angina pectoris; Had myocardial infarction or bypass or stent surgery within 6 months before the drug administration; Meet in New YorkA history of chronic heart failure at NYHA level 3-4; Valvular disease with clinical significance; Need to beTreated severe arrhythmia (except atrial fibrillation and paroxysmal supraventricular tachycardia), including QTc interphase male ≥450ms, female ≥470ms (calculated by Fridericia formula); Left ventricular ejection fraction (LVEF) < 50%;Cerebrovascular accident (CVA) or transient ischemic attack (TIA) etc. occurred within 6 months before the administration;
  9. Other serious medical conditions, including but not limited to: uncontrolled diabetes, active digestive tract ulcers,Active hemorrhage, etc;
  10. Active infectious persons requiring systemic treatment;
  11. Previous or current active TB infectious patient;
  12. Human immunodeficiency virus antibody (hiv-ab) and treponema pallidum antibody (tp-ab) were positive. Hepatitis c antibody (HCV-Ab) positive, and the upper limit of normal value of HCV RNA quantitative > detection unit; Hepatitis b virus surface antigen (HBsAg)Positive, and HBV DNA quantitative > detection unit normal limit;
  13. Complications that require systemic immunosuppressive drug therapy or that require an immunosuppressive dose (prednisone)> 10 mg/ day or equivalent dose of similar drugs) systemic treatment complications; In the absence of active autoimmune diseaseIn this case, inhaled or locally administered steroids and > 10mg/ d prednisone or equivalent dose are allowed;
  14. Adverse reactions from previous treatment did not return to level 1 or below before medication (CTCAE5.0) (alopecia and chemotherapyDrug induced grade 2 neurotoxicity excepted);
  15. Uncontrolled or symptomatic pleural or pericardial effusion;
  16. Previous use of anti-pd-1 antibodies, anti-pd-l1 antibodies, anti-pd-l2 antibodies or anti-ctla-4 antibodies (orAny other antibodies that act on T cell synergistic stimulation or checkpoint pathways);
  17. Other experimental drugs or experimental instruments were used within 30 days before administration;
  18. Live or attenuated vaccines were administered within 4 weeks of trial administration;
  19. A history of drug abuse or drug abuse was enquired;
  20. History of interstitial lung disease;
  21. Lactating women who do not want to stop breastfeeding;
  22. Known allergy to recombinant humanized pd-1 monoclonal antibody or any of its excipients; A known history of allergic disease or severe allergies;
  23. Patients with insufficient communication, understanding and cooperation, or poor compliance, can not be guaranteed to follow the program requirements;
  24. The researchers concluded that participants in this clinical trial were not suitable for a variety of other reasons.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Shawn Yu, Master 86-010-65260820
Listed Location Countries  ICMJE China
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03639181
Other Study ID Numbers  ICMJE Gxplore-003
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Genor Biopharma Co., Ltd.
Study Sponsor  ICMJE Genor Biopharma Co., Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Yuankai Shi, Doctor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PRS Account Genor Biopharma Co., Ltd.
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP